# EDGAR Filing Document

**Accession Number:** 0001734768
**File Stem:** 0001176256-23-000065
**Filing Date:** 2023-3
**Character Count:** 8763
**Document Hash:** 8da8a5eb07890af07f857e4b88859023
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001176256-23-000065.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001176256-23-000065

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230331

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMV Inc.
- **CENTRAL INDEX KEY:** 0001734768
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38480
- **FILM NUMBER:** 23788105

**BUSINESS ADDRESS:**
- **STREET 1:** 130 EILEEN STUBBS AVE.
- **STREET 2:** SUITE 19
- **CITY:** DARTMOUTH
- **STATE:** A5
- **ZIP:** B3B 2C4
- **BUSINESS PHONE:** 9024921819

**MAIL ADDRESS:**
- **STREET 1:** 130 EILEEN STUBBS AVE.
- **STREET 2:** SUITE 19
- **CITY:** DARTMOUTH
- **STATE:** A5
- **ZIP:** B3B 2C4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Immunovaccine Inc.
- **DATE OF NAME CHANGE:** 20180316

------

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March, 2023**

Commission File Number: **001-38480**

**<u>IMV Inc.</u>**<br> (*Name of registrant*)

**130 Eileen Stubbs Avenue, Suite 19 <br>Dartmouth, Nova Scotia <br><u>B3B 2C4, Canada</u>**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

[ X ] Form 20-F [ ] Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]<br>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMV Inc.** | **IMV Inc.** |
| Date: March 31, 2023 | By: | <u>/s/ Brittany Davison</u> |
|  |  | Name: Brittany Davison |
|  |  | Title: Chief Accounting Officer |

---

------

**Form 6-K Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Document Description** |
| [99.1](exhibit99-1.htm) | [IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency](exhibit99-1.htm) |

---

------

## Exhibit 99.1

------

**Exhibit 99.1** <br>

Media Release ![](exhibit99-1x1x1.jpg) <br>

**IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency**

**DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.** – **March 31, 2023** -- IMV Inc. ("**IMV**" or the "**Company**") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX<sup>™</sup> platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between February 14, 2023, through March 28, 2023, the Company did not meet the minimum bid price of US$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common shares on the Nasdaq Capital Market.

The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until September 25, 2023 (the "Compliance Period"), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In order to regain compliance with Nasdaq's minimum bid price requirement, the Company's common shares must maintain a minimum closing bid price of at least US$1.00 for a minimum of ten consecutive business days during the Compliance Period.

In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, the Company may face delisting.

The letter has no immediate impact on the Company's business operations or listing of the Company's common shares, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company's compliance with the other listing requirements of The Nasdaq Capital Market, as well as on the TSX.

**About IMV**

IMV Inc. is a clinical-stage biopharmaceutical company developing a novel class of cancer vaccines based on DPX®, our immune-educating technology platform. DPX is designed to inform a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers. DPX can package a wide range of bioactive molecules in a single formulation to incite the tumor-killing function of multiple, distinct immune cell subtypes. IMV's lead therapeutic candidate, maveropepimut-S (MVP-S), is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. Together, these elements are designed to foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function that drive a targeted, sustained immune response. In our clinical trials, MVP-S treatment has been well tolerated and has demonstrated favorable clinical outcomes in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is administered in very low doses approximately once every two months, which drives a persistent immune attack on tumor cells. MVP-S is currently being evaluated in Phase 2B clinical trials for advanced r/r Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer. IMV is also developing a dual-targeted cancer vaccine candidate leveraging the DPX delivery platform, DPX-SurMAGE. This cancer vaccine combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. For more information, visit <u>www.imv-inc.com</u> and connect with us on <u>Twitter</u> and <u>LinkedIn</u><u>.</u><br>

------

**IMV Forward-Looking Statements**

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as "will", "may", "potential", "believe", "expect", "continue", "anticipate" and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In this press release, such forward-looking statements include, but are not limited to, statements regarding IMV's ability to maintain its Nasdaq listing. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the Company's expected timeline associated with its cash runway; the Company's priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as others risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at <u>www.sedar.com</u> and on EDGAR at <u>www.sec.gov/edgar</u>.

**Investor Relations & Media**

**Delphine Davan<br>Senior Director, Communications and Investor Relations <br>IMV Inc.**

O: (902) 492.1819 ext: 1049 <br>E: <u>ddavan@imv-inc.com</u>

Source: IMV Inc.<br>

------